文献速递核素与放射性配体治疗肿瘤 PET/CT

玻璃微球90Y放射栓塞治疗结直肠癌肝转移的剂量-反应与剂量-毒性关系

Dose-Response and Dose-Toxicity Relationships for Glass 90Y Radioembolization in Patients with Liver Metastases from Colorectal Cancer.
PubMed 文献 · J Nucl Med · 2021-03-19

研究发现肿瘤吸收剂量与代谢反应存在显著剂量-反应关系,完全缓解和部分缓解病灶的剂量显著高于进展病灶;肿瘤吸收剂量>139 Gy预测3个月代谢反应的准确性最高(特异性89%、敏感性77%),而健康肝吸收剂量中位63 Gy时毒性多为1-2级。

要点

  • 肿瘤吸收剂量与代谢反应显著相关,完全缓解和部分缓解病灶剂量高于进展病灶。
  • 肿瘤吸收剂量>139 Gy预测3个月代谢反应准确性最高,特异性89%、敏感性77%。
  • 健康肝吸收剂量中位63 Gy,毒性主要为1-2级,仅1例放射性栓塞诱导肝病。

核心结论

  • 玻璃90Y放射栓塞治疗结直肠癌肝转移患者中观察到显著的剂量-反应关系。

研究设计与样本

  • 对85个可测量转移灶(18F-FDG阳性且肿瘤体积>5 cm3)在治疗后90Y PET上计算肿瘤吸收剂量。
  • 在基线和治疗后3个月通过18F-FDG PET/CT测量总病灶糖酵解确定代谢肿瘤反应。
  • 采用线性混合效应回归模型在病灶水平和患者水平分析肿瘤吸收剂量与代谢反应的关系。
  • 将临床毒性和实验室毒性与健康肝吸收剂量进行相关性分析。

主要发现

  • 85个可测量转移灶的中位肿瘤吸收剂量为133 Gy(范围20-1001 Gy)。
  • 按反应类别,完全缓解病灶为196 Gy,部分缓解为177 Gy,稳定疾病为72 Gy,进展疾病为95 Gy。
  • 在肿瘤水平发现显著剂量-反应关系,完全缓解(+94%)和部分缓解(+74%)转移灶的肿瘤吸收剂量显著高于进展疾病转移灶(P < 0.001)。
  • 在患者水平发现类似关系,部分缓解患者的肿瘤吸收剂量高于进展疾病患者(+58%,P = 0.044)。
  • 肿瘤吸收剂量>139 Gy预测3个月代谢反应准确性最高(特异性89%、敏感性77%),>189 Gy预测反应的特异性97%、敏感性45%。

关键数值与推荐

  • 肿瘤吸收剂量>139 Gy预测3个月代谢反应:特异性89%、敏感性77%。
  • 肿瘤吸收剂量>189 Gy预测反应:特异性97%、敏感性45%。
  • 可测量转移灶定义:18F-FDG阳性且肿瘤体积>5 cm3。

临床怎么用

  • 玻璃90Y放射栓塞治疗结直肠癌肝转移可参考肿瘤吸收剂量与代谢反应的剂量-反应关系进行个性化治疗计划。
  • 肿瘤吸收剂量>139 Gy与较高的3个月代谢反应预测准确性相关,可作为剂量目标参考。
  • 健康肝吸收剂量中位63 Gy时毒性多为1-2级,但最高健康肝吸收剂量患者出现放射性栓塞诱导肝病,需关注肝脏剂量与毒性。

局限性

  • 毒性分析中大多数实验室参数仅显示阳性趋势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radioembolization based on personalized treatment planning requires established dose-response and dose-toxicity relationships. The aim of this study was to investigate dose-response and dose-toxicity relationships in patients with colorectal liver metastases (CRLMs) treated with glass 90Y-microspheres. Methods: All CRLM patients treated with glass 90Y-microspheres in our institution were retrospectively analyzed. The tumor-absorbed dose was calculated for each measurable metastasis (i.e.,18F-FDG-positive and more than a 5-cm3 tumor volume) on posttreatment 90Y PET. Metabolic tumor response was determined on 18F-FDG PET/CT by measuring the total lesion glycolysis at baseline and at 3 mo after treatment. The relationship between tumor-absorbed dose and metabolic response was determined on a per-lesion and per-patient basis using a linear mixed-effects regression model. Clinical toxicity and laboratory toxicity were correlated with healthy liver-absorbed dose. Results: Thirty-one patients were included. The median tumor-absorbed dose of 85 measurable metastases was 133 Gy (range, 20-1001 Gy). Per response category, this was 196 Gy for complete response (CR), 177 Gy for partial response (PR), 72 Gy for stable disease, and 95 Gy for progressive disease (PD). A significant dose-response relationship was found on a tumor level, with a significantly higher tumor-absorbed dose in metastases with CR (+94%) and PR (+74%) than in metastases with PD (P < 0.001). A similar relationship was found on a patient level, with PR having a higher tumor-absorbed dose than did PD (+58%, P = 0.044). A tumor-absorbed dose of more than 139 Gy predicted a 3-mo metabolic response with the greatest accuracy (89% specificity and 77% sensitivity), whereas a tumor-absorbed dose of more than 189 Gy predicted response with 97% specificity and 45% sensitivity. The median healthy liver-absorbed dose was 63 Gy (range, 24-113 Gy). Toxicity was limited mostly to grades 1 and 2, with 1 case of radioembolization-induced liver disease in a patient who received the highest healthy liver-absorbed dose. A positive trend was seen for most laboratory parameters in our dose-toxicity analysis. Conclusion: A significant relationship was observed between dose and response in CRLM patients treated with glass 90Y radioembolization.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Alsultan AA, van Roekel C, Barentsz MW, et al. Dose-Response and Dose-Toxicity Relationships for Glass 90Y Radioembolization in Patients with Liver Metastases from Colorectal Cancer. J Nucl Med. 2021. PMID: 33741643. doi:10.2967/jnumed.120.255745

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。